Bobbi Coffin Named to Business Advisory Board
Biodesix Exec and Former Exact Sciences Commercial Leader Adds Marketing Depth to Board Denver, CO – May 5, 2022 – HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that Bobbi Coffin, has joined the company’s…
Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial
Pharma and Medical Device Veteran Ally Xu Named Director of Regulatory and Quality Affairs
HepQuant Names Pharma and Medical Device Veteran Ally Xu Director of Regulatory and Quality Affairs DENVER (Feb. 1, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that pharmaceutical and medical device industry veteran…
Preliminary data from the HepQuant SHUNT-V Pivotal study released during the 72nd AASLD Annual Meeting
HepQuant Results Presented while Attending the 72nd AASLD Annual Meeting and AHA 2021 Annual Meeting DENVER (November 16th, 2021) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that preliminary data from the SHUNT-V Pivotal study…
Perspectum and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health
Perspectum and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health Partnership Combines Imaging and Functional Assessment for Clinical Research San Francisco, CA and Denver, CO – Nov. 1, 2021. Perspectum and HepQuant are proud to announce a strategic business partnership to provide seamless delivery of HepQuant’s…
HepQuant’s Greg Everson, MD, to Speak at AASLD/FDA Conference on Drug-Induced Liver Injury (DILI)
HepQuant’s Greg Everson, MD, to Speak at AASLD/FDA Conference on Drug-Induced Liver Injury (DILI) DENVER (April 14th, 2021) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that it will present at the 2021 AASLD/FDA Conference…
HepQuant Promotes Sean Bundy to Chief Operating Officer
HepQuant Promotes Sean Bundy, RAC, to Chief Operating Officer Denver, CO – June 10, 2020 – HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced the promotion of Sean Bundy, RAC, to the…
HepQuant to Offer Mobile and Remote Test Administration via CVS Health’s Coram Clinical Trials
HepQuant to Offer Mobile and Remote Test Administration in Clinical Trials via CVS Health’s Coram Clinical Trials DENVER (February 18th, 2020) — HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending blood-based technology for evaluating the function of the liver, today announced that it will now offer…
HepQuant to Present at Biotech Showcase™ 2020
HepQuant to Present at Biotech Showcase™ 2020 San Francisco Event to be held January 13–15th DENVER (Jan. 10, 2020) — HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending blood-based technology for evaluating the function of the liver, today announced that it has scheduled a company presentation at…
HepQuant’s Disease Severity Index (DSI) Demonstrates Hepatic Functional Improvement in High Percentage of NASH Patients Treated with Obeticholic Acid: Results from INTERCEPT 747-117
HepQuant’s Disease Severity Index (DSI) Demonstrates Hepatic Functional Improvement in High Percentage of NASH Patients Treated with Obeticholic Acid: Results from INTERCEPT 747-117 The First HepQuant SHUNT™ Data From An Interventional Drug Study in NASH DENVER (April 4, 2019) — HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique,…